Trial Profile
An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 30 Aug 2018 New trial record